Drug intelligence / Profile preview

cisplatin + vindesine + dacarbazine

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

This combination is used in chemotherapy, primarily for treating advanced cancers such as malignant melanoma and lung carcinoma. **Cisplatin** is a platinum-based antineoplastic drug that works by cross-linking DNA, which interferes with cell division. **Vindesine** is a vinca alkaloid that inhibits microtubule assembly, disrupting cell division. **Dacarbazine** is an alkylating agent that damages DNA, preventing cancer cells from reproducing.

Targets

MicrotubuleDNA

Beyond the preview

Go deeper on cisplatin + vindesine + dacarbazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + vindesine + dacarbazine.

Explore the full profile